Key Points
- Insider buying: Chase Leavitt purchased 2,000 Mobia Medical shares at $10.30 each for $20,600, increasing his direct stake by 66.67% to 5,000 shares.
- Mixed financial results: Quarterly revenue more than doubled year over year to $13.51 million, but the company reported an adjusted loss of $1.10 per share, missing estimates of an $0.83 loss.
- Analyst outlook remains moderately positive: Five analysts rate the stock Buy, one Hold, and one Sell, producing a consensus “Moderate Buy” rating and a $20.75 price target, despite shares opening at $10.77.
Mobia Medical, Inc. (NASDAQ:MOBI - Get Free Report) insider Chase Leavitt purchased 2,000 shares of the company's stock in a transaction dated Friday, September 11th. The shares were acquired at an average price of $10.30 per share, for a total transaction of $20,600.00. Following the purchase, the insider directly owned 5,000 shares of the company's stock, valued at approximately $51,500. The trade was a 66.67% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.
Mobia Medical Stock Up 7.4%
MOBI opened at $10.77 on Wednesday. The firm has a market capitalization of $358.53 million and a P/E ratio of -0.53. The company has a current ratio of 13.28, a quick ratio of 12.80 and a debt-to-equity ratio of 0.04. The firm's 50-day moving average is $11.48. Mobia Medical, Inc. has a 52-week low of $9.85 and a 52-week high of $15.29.
Mobia Medical (NASDAQ:MOBI - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.27). The business had revenue of $13.51 million for the quarter. The business's revenue was up 102.4% compared to the same quarter last year. On average, research analysts anticipate that Mobia Medical, Inc. will post -2.63 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts have weighed in on the company. Zacks Research upgraded Mobia Medical to a "hold" rating in a research note on Wednesday, June 3rd. The Goldman Sachs Group started coverage on Mobia Medical in a research note on Tuesday, June 2nd. They issued a "buy" rating and a $31.00 price objective for the company. Wolfe Research started coverage on Mobia Medical in a report on Tuesday, June 2nd. They set an "outperform" rating for the company. Weiss Ratings assumed coverage on Mobia Medical in a research report on Wednesday, August 12th. They issued a "sell (e-)" rating on the stock. Finally, JPMorgan Chase & Co. increased their price target on shares of Mobia Medical from $15.00 to $17.00 and gave the stock an "overweight" rating in a report on Wednesday, August 12th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Mobia Medical has a consensus rating of "Moderate Buy" and a consensus price target of $20.75.
Check Out Our Latest Stock Analysis on Mobia Medical
Institutional Trading of Mobia Medical
A hedge fund recently bought a new position in Mobia Medical stock. Readystate Asset Management LP bought a new position in shares of Mobia Medical, Inc. (NASDAQ:MOBI - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 10,000 shares of the company's stock, valued at approximately $134,000.
Mobia Medical Company Profile
(
Get Free Report)
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
